Cointime

InterveXion Therapeutics

company

About

InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical company

  • 51 - 100

Highlights

Total Funding Amount
$52.80M
Funding Rounds
5
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$13.80M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2004
Number Of Employee
51 - 100
Operating Status
Active

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$52.80M
InterveXion Therapeutics has raised a total of $52.80M in funding over 2 rounds. Their latest funding was raised on Nov 1, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 1, 2021 Grant $13.80M 1 National Institutes of Health — Detail
Oct 5, 2020 Grant $8.10M 1 — — Detail
May 5, 2020 Grant $8.40M 1 — — Detail
Oct 10, 2017 Grant $8M 1 — — Detail
Jan 29, 2015 Grant $14.50M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
InterveXion Therapeutics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Cointime
เนื้อหา
บริษัท